Zobrazeno 1 - 10
of 17
pro vyhledávání: '"E. S. Siris"'
Autor:
M. S. LeBoff, S. L. Greenspan, K. L. Insogna, E. M. Lewiecki, K. G. Saag, A. J. Singer, E. S. Siris
Publikováno v:
Osteoporosis International. 33:2243-2243
Autor:
M. S. LeBoff, S. L. Greenspan, K. L. Insogna, E. M. Lewiecki, K. G. Saag, A. J. Singer, E. S. Siris
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 33(10)
Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a subclinical condition until complicated by fracture(s). These fractures place an enormous medical and personal burden on individuals who suffer from them and tak
Autor:
E. S. Siris, A. Tosteson, Bengt Jönsson, J. A. Kanis, John A. Eisman, Alexandra Papaioannou, O. Ström
Publikováno v:
Osteoporosis International. 23:2063-2065
Autor:
E. S. Siris
Publikováno v:
Journal of Clinical Endocrinology & Metabolism. 80:335-338
Autor:
E. S. Siris, L. E. Wehren
Publikováno v:
Journal of internal medicine. 256(5)
Wehren LE, Siris ES (University of Maryland School of Medicine, Baltimore, MD; and Columbia University College of Physicians and Surgeons, New York, NY) Beyond bone mineral density: can existing clinical risk assessment instruments identify women at
Autor:
P D, Miller, S L, Bonnick, C C, Johnston, M, Kleerekoper, R L, Lindsay, L M, Sherwood, E S, Siris
Publikováno v:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 1(3)
Lower cost, portable, peripheral bone mass measurement devices are being increasingly utilized for widespread bone mass testing. These devices are being placed in traditional medical settings as well as nontraditional settings, such as pharmacies and
Publikováno v:
The American journal of medicine. 106(5)
To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget's disease of bone.Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for
Autor:
E S, Siris, F, Feldman
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 12(4)
Autor:
R Canfield, M E Wootten, E S Siris, G V Cochran, R Lindsay, H. K. Ramakrishnan, J. Gainey, M P Kadaba
Publikováno v:
The Journal of Bone & Joint Surgery. 71:568-579
Eighteen patients who had Paget disease were evaluated in our gait-analysis laboratory. The results were compared with those of ten healthy age-matched control subjects in order to quantitate the biomechanical changes and to describe the specific pat
Publikováno v:
The American journal of medicine. 82(2)
A patient with a mesenchymal tumor and hypophosphatemic osteomalacia was studied before and after tumor excision. Initial laboratory values included normal serum calcium, decreased serum phosphorus and tubular reabsorption of phosphate, undetectable